| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Gregory Porras, Amandine Berthet, Benjamin Dehay, Qin Li, Laurent Ladepeche, Elisabeth Normand, Sandra Dovero, Audrey Martinez, Evelyne Doudnikoff, Marie-Laure Martin-Négrier, Qin Chuan, Bertrand Bloch, Daniel Choquet, Eric Boué-Grabot, Laurent Groc, Erwan Bezar. PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking. The Journal of clinical investigation. vol 122. issue 11. 2013-01-15. PMID:23041629. |
l-dopa-induced dyskinesia (lid), a detrimental consequence of dopamine replacement therapy for parkinson's disease, is associated with an alteration in dopamine d1 receptor (d1r) and glutamate receptor interactions. |
2013-01-15 |
2023-08-12 |
rat |
| Christopher Bishop, Jessica A George, William Buchta, Adam A Goldenberg, Mohamed Mohamed, Sando O Dickinson, Satie Eissa, Karen L Eskow Jaunaraj. Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats. The European journal of neuroscience. vol 36. issue 6. 2013-01-09. PMID:22762478. |
long-term dopamine replacement therapy with l-dopa in parkinson's disease often leads to the development of abnormal involuntary movements known as l-dopa-induced dyskinesia. |
2013-01-09 |
2023-08-12 |
rat |
| Christopher Bishop, Jessica A George, William Buchta, Adam A Goldenberg, Mohamed Mohamed, Sando O Dickinson, Satie Eissa, Karen L Eskow Jaunaraj. Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats. The European journal of neuroscience. vol 36. issue 6. 2013-01-09. PMID:22762478. |
growing evidence suggests that, following dopamine cell loss, serotonin neurons acting as surrogates for dopaminergic processes take up l-dopa, convert it to dopamine and release it in an unregulated fashion that precipitates dyskinesia. |
2013-01-09 |
2023-08-12 |
rat |
| George B Stefano, Kirk J Mantione, Milena Králíčková, Radek Ptacek, Hana Kuzelova, Tobias Esch, Richard M Krea. Parkinson's disease, L-DOPA, and endogenous morphine: a revisit. Medical science monitor : international medical journal of experimental and clinical research. vol 18. issue 8. 2012-12-18. PMID:22847214. |
clinical observations stemming from widespread employment of restorative l-3,4-dihydroxyphenylalanine (l-dopa) therapy for management of dyskinesia in parkinson's disease (pd) patients implicate a regulatory role for endogenous morphine in central nervous system dopamine neurotransmission. |
2012-12-18 |
2023-08-12 |
human |
| Anupom Borah, Kochupurackal P Mohanakuma. L-DOPA induced-endogenous 6-hydroxydopamine is the cause of aggravated dopaminergic neurodegeneration in Parkinson's disease patients. Medical hypotheses. vol 79. issue 2. 2012-11-30. PMID:22641021. |
dopamine replacement therapy by 3,4-dihydroxyphenylalanine (l-dopa), which is the gold standard symptomatic treatment for the parkinson's disease (pd), frequently leads to potential debilitating side-effects such as dyskinesia. |
2012-11-30 |
2023-08-12 |
human |
| Eunju Shin, Joanna Garcia, Christian Winkler, Anders Björklund, Manolo Cart. Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease. Neurobiology of disease. vol 47. issue 3. 2012-11-29. PMID:22579773. |
dyskinesia seen in the off-state, referred as graft-induced dyskinesia (gid), has emerged as a serious complication induced by dopamine (da) cell transplantation in parkinsonian patients. |
2012-11-29 |
2023-08-12 |
rat |
| Tarannum S Kha. Off spells and dyskinesias: pharmacologic management of motor complications. Cleveland Clinic journal of medicine. vol 79 Suppl 2. 2012-11-06. PMID:22761271. |
there are two major causes of disability in patients with parkinson disease: motor fluctuations that occur when a dose of levodopa becomes ineffective, leading to a "wearing off," and hyperkinetic movements (dyskinesias) caused by excessive levels of dopamine. |
2012-11-06 |
2023-08-12 |
Not clear |
| M A Hely, J G Morris, R J Burns, C M Lander, D B McLaughlin, G A Donna. An Australian multicentre open label study of pergolide as an adjunct to levodopa in Parkinson's disease. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. vol 3. issue 3. 2012-10-02. PMID:18638876. |
the efficacy and side effects of pergolide, a d(1) and d(2) dopamine agonist, were assessed in an open label study in 39 patients with long standing parkinson's disease complicated by end of dose failure and/or dyskinesia. |
2012-10-02 |
2023-08-12 |
Not clear |
| J Gerlach, L Hanse. Effect of chronic treatment with NNC 756, a new D-1 receptor antagonist, or raclopride, a D-2 receptor antagonist, in drug-naive Cebus monkeys: dystonia, dyskinesia and D-1/D-2 supersensitivity. Journal of psychopharmacology (Oxford, England). vol 7. issue 4. 2012-10-02. PMID:22290999. |
withdrawal of raclopride as well as nnc 756 led to behavioural d-1 and d-2 dopamine supersensitivity in the form of increased dyskinesia (including grooming after nnc 756) induced by d-1 agonist (skf 81297) and increased arousal induced by d-2 agonist (quinpirole). |
2012-10-02 |
2023-08-12 |
monkey |
| Kazuhiro Takuma, Tatsunori Tanaka, Tsuyoshi Takahashi, Naoki Hiramatsu, Yuki Ota, Yukio Ago, Toshio Matsud. Neuronal nitric oxide synthase inhibition attenuates the development of L-DOPA-induced dyskinesia in hemi-Parkinsonian rats. European journal of pharmacology. vol 683. issue 1-3. 2012-09-13. PMID:22449381. |
long-term treatment with the dopamine precursor levodopa (l-dopa) frequently induces dyskinesia in parkinson's disease patients, which is a major complication of this therapy. |
2012-09-13 |
2023-08-12 |
rat |
| Claire Thiriez, Gabriel Villafane, Frédérique Grapin, Gilles Fenelon, Philippe Remy, Pierre Cesar. Can nicotine be used medicinally in Parkinson's disease? Expert review of clinical pharmacology. vol 4. issue 4. 2012-09-04. PMID:22114853. |
however, nicotine may modulate dopamine transmission and has clear motor effects when associated with l-dopa, reducing l-dopa-induced dyskinesias. |
2012-09-04 |
2023-08-12 |
Not clear |
| Daniela Calandrella, Angelo Antonin. Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease. Parkinsonism & related disorders. vol 18 Suppl 1. 2012-08-27. PMID:22166407. |
all studies comparing levodopa versus dopamine agonist early therapy indicate that initiation with agonists is associated with a reduced risk of motor complications - in particular, dyskinesias - possibly because agonists' longer half-lives provide continuous dopaminergic delivery. |
2012-08-27 |
2023-08-12 |
Not clear |
| Daniella Rylande. The serotonin system: a potential target for anti-dyskinetic treatments and biomarker discovery. Parkinsonism & related disorders. vol 18 Suppl 1. 2012-08-27. PMID:22166409. |
however, the terminals represent an aberrant source of dopamine release, increasing the risk for dyskinesia. |
2012-08-27 |
2023-08-12 |
Not clear |
| Maryka Quik, Keon Min Park, Maya Hrachova, Archana Mallela, Luping Z Huang, J Michael McIntosh, Sharon R Grad. Role for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice. Neuropharmacology. vol 63. issue 3. 2012-08-27. PMID:22579614. |
l-dopa-induced dyskinesias are a serious side effect that develops in most parkinson's disease patients on dopamine replacement therapy. |
2012-08-27 |
2023-08-12 |
mouse |
| John C P Piedad, Andrea E Cavann. Dyskinesias and treatment with pramipexole in patients with Parkinson's disease. Parkinson's disease. vol 2012. 2012-08-23. PMID:22496989. |
dopamine agonists such as pramipexole (ppx) have first been proposed as adjunctive treatment to levodopa (l-dopa) for patients with parkinson's disease (pd) and then as a monotherapy alternative to alleviate dyskinesia. |
2012-08-23 |
2023-08-12 |
Not clear |
| Nicola Tambasco, Simone Simoni, Erica Marsili, Elisa Sacchini, Donatella Murasecco, Gabriela Cardaioli, Aroldo Rossi, Paolo Calabres. Clinical aspects and management of levodopa-induced dyskinesia. Parkinson's disease. vol 2012. 2012-08-23. PMID:22701811. |
strategies to delay or to reduce dyskinesias are based on the change of levodopa dosing or the early use of dopamine agonists. |
2012-08-23 |
2023-08-12 |
Not clear |
| Nicola Tambasco, Simone Simoni, Erica Marsili, Elisa Sacchini, Donatella Murasecco, Gabriela Cardaioli, Aroldo Rossi, Paolo Calabres. Clinical aspects and management of levodopa-induced dyskinesia. Parkinson's disease. vol 2012. 2012-08-23. PMID:22701811. |
our paper was aimed to analyse the clinical impact and the management of dyskinesias with dopamine agonists. |
2012-08-23 |
2023-08-12 |
Not clear |
| Xue-Bing Cao, Qiang Guan, Yan Xu, Lan Wang, Sheng-Gang Su. Mechanism of over-activation in direct pathway mediated by dopamine D₁ receptor in rats with levodopa-induced dyskinesia. Neuroscience bulletin. vol 22. issue 3. 2012-06-25. PMID:17704844. |
mechanism of over-activation in direct pathway mediated by dopamine d₁ receptor in rats with levodopa-induced dyskinesia. |
2012-06-25 |
2023-08-12 |
rat |
| Xue-Bing Cao, Qiang Guan, Yan Xu, Lan Wang, Sheng-Gang Su. Mechanism of over-activation in direct pathway mediated by dopamine D₁ receptor in rats with levodopa-induced dyskinesia. Neuroscience bulletin. vol 22. issue 3. 2012-06-25. PMID:17704844. |
to study the changes of prodynorphin (pdyn) gene expression and dopamine and camp-regulated phosphoprotein of 32 kda (darpp-32) phosphorylation in rats with levodopa-induced dyskinesia (lid), and to explore the mechanism of over-activation in direct pathway mediated by dopamine d₁ receptor. |
2012-06-25 |
2023-08-12 |
rat |
| Joanna García, Thomas Carlsson, Máté Döbrössy, Guido Nikkhah, Christian Winkle. Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia. Neurobiology of disease. vol 43. issue 3. 2012-05-21. PMID:21600983. |
impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and l-dopa-induced dyskinesia. |
2012-05-21 |
2023-08-12 |
rat |